FirmaIQ
Org.nr 815 643 062 2022 → 2023 Year-over-year analysis

ADESSO BIOPRODUCTS AS: årsregnskap 2023 vs 2022

Shrank 19% on revenue, weaker earnings

approved 2024-04-25; registry 2024-05-29; journal 2024 391900

Full company analysis · All year comparisons

Summary

What changed

Comparing Årsregnskap 2023 with 2022 for ADESSO BIOPRODUCTS AS. Revenue 105.37m NOK → 85.69m NOK (-18.7%). Net result +5.21m NOK → +3.76m NOK. Equity 37.85m NOK → 41.61m NOK.

On the constructive side: equity strengthened. Pressures included: revenue fell; operating result weakened; net result weakened.

Also worth watching: cogs fell. All figures are taken from the published annual accounts for ADESSO BIOPRODUCTS AS.

At a glance

Scorecard

Revenue
105.37m NOK 85.69m NOK
-18.7%
Operating result
+7.02m NOK +5.81m NOK
-17.3%
Net result
+5.21m NOK +3.76m NOK
-27.8%
Equity
37.85m NOK 41.61m NOK
+9.9%
Cash
21.65m NOK 18.21m NOK
-15.9%
Total assets
80.63m NOK 66.31m NOK
-17.8%

What improved

  • ↑

    Equity strengthened

    Book equity 37.85m NOK → 41.61m NOK (equity ratio 46.9% → 62.7%). Calculated

What deteriorated

  • ↓

    Revenue fell

    Operating income / revenue moved from 105.37m NOK to 85.69m NOK (-18.7% YoY). Calculated

  • ↓

    Operating result weakened

    Operating result +7.02m NOK → +5.81m NOK (op. margin 6.7% → 6.8%). Calculated

  • ↓

    Net result weakened

    Net result +5.21m NOK → +3.76m NOK (net margin 4.9% → 4.4%). Calculated

  • ↓

    Cash fell

    Bank deposits 21.65m NOK → 18.21m NOK (-15.9% YoY). Calculated

  • ↓

    Payroll up without matching revenue

    Salary cost 15.83m NOK → 16.66m NOK (15% → 19% of revenue). Calculated

Things to notice

  • ·

    COGS fell

    COGS / varekostnad 60.18m NOK → 41.17m NOK (-31.6% YoY). Calculated